- Poster presentation
- Open Access
HIV-1 subtype B- and F1-infected subjects display higher cross-clade T-Cell response than subtype C-infected subjects
Retrovirology volume 9, Article number: P150 (2012)
The impact of the extensive genetic diversity of the HIV-1 group M isolates and its implications for vaccine design have long been discussed. Studies indicate that Gag and Nef conserved epitopes are commonly recognized and give rise to high cross-clade responses. The aim of this study was to compare T-cell responses to peptide pools derivate from subtype B, C and F1 consensus, among Brazilian subjects infected with those three HIV-1 subtypes.
The study included 32 subjects infected with HIV-1 subtypes B (n=13), C (n=11) and F1 (n=8). Gag and Nef-specific T cell responses were evaluated by IFN-γ ELISpot assay, using peptide pools based on subtype B, C and F1 Brazilians consensus.
A high cross-clade response between subtypes B and F1 for both Gag and Nef regions was observed among HIV-1 subtype B- and F1-infected subjects. We also found no significant difference in magnitude of responses between subtype B and C consensus peptides in subtype B-infected subjects.In contrast, the magnitude of T cell responses to consensus C peptides in Gag region was significantly higher than to consensus B peptides among HIV-1 subtype C-infected subjects. In Nef, subtype C-infected subjects showed higher T cell responses to C than to F1 consensus peptides. Moreover, subtype F1-infected subjects presented lower responses to subtype C peptides than to subtype F1 and B ones.
Overall, the level of cross-clade response between subtypes B and F1 was higher than between subtype C and B or between subtype C and F1. Our data suggest that significance of the HIV-1 group M genetic diversity for vaccine design may be dependent of the subtypes involved.
About this article
Cite this article
Côrtes, F., Bello, G., Vorsatz, C. et al. HIV-1 subtype B- and F1-infected subjects display higher cross-clade T-Cell response than subtype C-infected subjects. Retrovirology 9, P150 (2012) doi:10.1186/1742-4690-9-S2-P150
- Genetic Diversity
- Infectious Disease
- Cancer Research
- Cell Response